United States - English - NLM (National Library of Medicine)

j. strickland & co. - pyrithione zinc (unii: r953o2rhz5) (pyrithione zinc - unii:r953o2rhz5) - controls scalp itching and flaking due to dandruff

European Union - English - EMA (European Medicines Agency)

valneva austria gmbh - japanese-encephalitis virus, inactivated (attenuated strain sa14-14-2 grown in vero cells) - encephalitis, japanese; immunization - vaccines - ixiaro is indicated for active immunisation against japanese encephalitis in adults, adolescents, children and infants aged two months and older.ixiaro should be considered for use in individuals at risk of exposure through travel or in the course of their occupation.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - valsartan, quantity: 320 mg; hydrochlorothiazide, quantity: 25 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; magnesium stearate; crospovidone; hypromellose; iron oxide yellow; purified talc; macrogol 4000; titanium dioxide - co-diovan is indicated for the treatment of hypertension. treatment should not be initiated with these combinations.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - hydrochlorothiazide, quantity: 12.5 mg; valsartan, quantity: 320 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; crospovidone; microcrystalline cellulose; magnesium stearate; hypromellose; purified talc; macrogol 4000; iron oxide red; iron oxide black; titanium dioxide - co-diovan is indicated for the treatment of hypertension. treatment should not be initiated with these combinations.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - valsartan, quantity: 160 mg; hydrochlorothiazide, quantity: 25 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; crospovidone; magnesium stearate; colloidal anhydrous silica; hypromellose; iron oxide yellow; purified talc; macrogol 4000; iron oxide red; iron oxide black; titanium dioxide - co-diovan is indicated for the treatment of hypertension. treatment should not be initiated with these combinations.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - hydrochlorothiazide, quantity: 12.5 mg; valsartan, quantity: 160 mg - tablet, film coated - excipient ingredients: crospovidone; microcrystalline cellulose; titanium dioxide; purified talc; iron oxide red; macrogol 8000; magnesium stearate; hypromellose; colloidal anhydrous silica - co-diovan is indicated for the treatment of hypertension. treatment should not be initiated with these combinations.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - hydrochlorothiazide, quantity: 12.5 mg; valsartan, quantity: 80 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; iron oxide yellow; colloidal anhydrous silica; crospovidone; purified talc; magnesium stearate; hypromellose; macrogol 8000; iron oxide red; titanium dioxide - co-diovan is indicated for the treatment of hypertension. treatment should not be initiated with these combinations.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

five star japan co p-l - paradichlorobenzene - household insecticide - pest control - carpet, woollen goods | carpet surface fibre | carpet underpadding | refer to label - moth | adult

United States - English - NLM (National Library of Medicine)

glaxosmithkline llc - dostarlimab (unii: p0gvq9a4s5) (dostarlimab - unii:p0gvq9a4s5) - jemperli, in combination with carboplatin and paclitaxel, followed by jemperli as a single agent, is indicated for the treatment of adult patients with primary advanced or recurrent endometrial cancer (ec) that is mismatch repair deficient (dmmr), as determined by an fda-approved test, or microsatellite instability-high (msi-h) [see dosage and administration ( 2.1)]. jemperli, as a single agent, is indicated for the treatment of adult patients with dmmr recurrent or advanced endometrial cancer, as determined by an fda-approved test, that has progressed on or following prior treatment with a platinum-containing regimen in any setting and are not candidates for curative surgery or radiation [see dosage and administration ( 2.1)]. jemperli, as a single agent, is indicated for the treatment of adult patients with dmmr recurrent or advanced solid tumors, as determined by an fda-approved test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options [see dosage and administration ( 2.1)]. this indication is approved under accelerated approval based on tumor response rate and durability of response [see clinical studies ( 14.2)] . continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). none. risk summary based on its mechanism of action, jemperli can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)] . there are no available data on the use of jemperli in pregnant women. animal studies have demonstrated that inhibition of the pd-1/pd-l1 pathway can lead to increased risk of immune-mediated rejection of the developing fetus resulting in fetal death (see data). human igg4 immunoglobulins (igg4) are known to cross the placental barrier; therefore, dostarlimab-gxly has the potential to be transmitted from the mother to the developing fetus. advise women of the potential risk to a fetus. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. data animal data: animal reproduction studies have not been conducted with jemperli to evaluate its effect on reproduction and fetal development. a central function of the pd-1/pd-l1 pathway is to preserve pregnancy by maintaining maternal immune tolerance to the fetus. in murine models of pregnancy, blockade of pd-l1 signaling has been shown to disrupt tolerance to the fetus and to result in an increase in fetal loss; therefore, potential risks of administering jemperli during pregnancy include increased rates of abortion or stillbirth. as reported in the literature, there were no malformations related to the blockade of pd-1/pd-l1 signaling in the offspring of these animals; however, immune-mediated disorders occurred in pd-1 and pd-l1 knockout mice. based on its mechanism of action, fetal exposure to dostarlimab-gxly may increase the risk of developing immune-mediated disorders or altering the normal immune response. risk summary there is no information regarding the presence of dostarlimab-gxly in human milk or its effects on the breastfed child or on milk production. maternal igg is known to be present in human milk. the effects of local gastrointestinal exposure and limited systemic exposure in the breastfed child to jemperli are unknown. because of the potential for serious adverse reactions in a breastfed child, advise women not to breastfeed during treatment and for 4 months after the last dose of jemperli. jemperli can cause fetal harm when administered to a pregnant woman [see use in specific populations (8.1)] . pregnancy testing verify pregnancy status in females of reproductive potential prior to initiating jemperli [see use in specific populations (8.1)]. contraception females: advise females of reproductive potential to use effective contraception during treatment with jemperli and for 4 months after the last dose. the safety and efficacy of jemperli have not been established in pediatric patients. in combination with carboplatin and paclitaxel of the 241 patients treated with jemperli in ruby, 52.3% were younger than 65 years, 36.5% were aged 65 through 75 years, and 11.2% were 75 years or older. no overall differences in safety or effectiveness were observed between these patients and younger patients. as a single agent of the 605 patients treated with jemperli in garnet, 51.6% were younger than 65 years, 36.9% were aged 65 through 75 years, and 11.5% were 75 years or older. no overall differences in safety or effectiveness were observed between these patients and younger patients.

United States - English - NLM (National Library of Medicine)

hospira, inc. - hydroxyethyl starch 130/0.4 (unii: 1gvo236s58) (hydroxyethyl starch 130/0.4 - unii:1gvo236s58) - hydroxyethyl starch 130/0.4 6 g in 100 ml - voluven ® (6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride injection) is indicated for the treatment and prophylaxis of hypovolemia in adults and children. it is not a substitute for red blood cells or coagulation factors in plasma. - do not use hydroxyethyl starch (hes) products, including voluven ® , in critically ill adult patients, including patients with sepsis, due to increased risk of mortality and renal replacement therapy (rrt). - do not use hes products, including voluven ® , in patients with severe liver disease. - do not use hes products, including voluven ® , in patients with known hypersensitivity to hydroxyethyl starch [see general warnings and precautions (5.1) ] - do not use hes products in clinical conditions with volume overload. - do not use hes products in patients with pre-existing coagulation or bleeding disorders. - do not use hes products in patients with renal failure with oliguria or anuria not related